Eupraxia Pharmaceuticals Inc
EPRX5.380USD
+0.120+2.28%
Handelsschluss 08/04, 16:00（ET）Kurse um 15 Minuten verzögert
192.87MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Eupraxia Pharmaceuticals Inc Unternehmen
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.
Unternehmensinformationen
BörsenkürzelEPRX
Name des UnternehmensEupraxia Pharmaceuticals Inc
IPO-datumMar 09, 2021
CEODr. James A. Helliwell, M.D.
Anzahl der mitarbeiter33
WertpapierartOrdinary Share
GeschäftsjahresendeMar 09
Addresse201-2067 Cadboro Bay Rd.
StadtVICTORIA
BörseThe Toronto Stock Exchange
LandCanada
PostleitzahlV8R 5G4
Telefon12505903968
Websitehttps://eupraxiapharma.com/home/default.aspx
BörsenkürzelEPRX
IPO-datumMar 09, 2021
CEODr. James A. Helliwell, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
224.87K
--
Dr. Amanda Malone
Dr. Amanda Malone
Chief Operating and Scientific Officer
Chief Operating and Scientific Officer
46.34K
+18.22%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
13.93K
--
Mr. Adam Peeler
Mr. Adam Peeler
Investor relations
Investor relations
--
--
Mr. Joseph Freedman
Mr. Joseph Freedman
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Mr. Paul A. Brennan
Mr. Paul A. Brennan
Chief Business Officer
Chief Business Officer
--
--
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Simon Pimstone, M.D., Ph.D.
Dr. Simon Pimstone, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Paul Geyer
Mr. Paul Geyer
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
224.87K
--
Dr. Amanda Malone
Dr. Amanda Malone
Chief Operating and Scientific Officer
Chief Operating and Scientific Officer
46.34K
+18.22%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
13.93K
--
Mr. Adam Peeler
Mr. Adam Peeler
Investor relations
Investor relations
--
--
Mr. Joseph Freedman
Mr. Joseph Freedman
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Mon, Jun 2
Aktualisiert: Mon, Jun 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Disbrow (Robert)
8.04%
Scotia Capital Inc.
4.32%
Freedman (Joseph S)
4.20%
Montalbano (John S.)
3.37%
Helliwell (James Allen)
1.87%
Other
78.19%
Aktionäre
Aktionäre
Anteil
Disbrow (Robert)
8.04%
Scotia Capital Inc.
4.32%
Freedman (Joseph S)
4.20%
Montalbano (John S.)
3.37%
Helliwell (James Allen)
1.87%
Other
78.19%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
19.13%
Research Firm
4.43%
Investment Advisor
1.64%
Hedge Fund
0.03%
Other
74.78%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
27
9.07M
25.23%
+3.18M
2025Q1
33
13.45M
37.66%
+9.00M
2024Q4
29
12.81M
35.95%
+8.38M
2024Q3
26
11.48M
34.74%
+5.59M
2024Q2
21
8.52M
26.42%
+4.35M
2024Q1
12
3.99M
17.06%
-637.88K
2023Q4
16
7.00M
38.32%
+2.38M
2023Q3
16
7.01M
38.38%
+2.38M
2023Q2
15
6.89M
39.05%
+2.27M
2023Q1
16
6.89M
40.01%
+2.40M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Disbrow (Robert)
2.89M
8.04%
+2.89M
--
Sep 30, 2024
Scotia Capital Inc.
1.55M
4.32%
+160.96K
+11.57%
Mar 31, 2025
Freedman (Joseph S)
1.51M
4.2%
+10.00K
+0.67%
Jun 18, 2025
Montalbano (John S.)
1.21M
3.37%
--
--
Apr 25, 2025
Helliwell (James Allen)
674.01K
1.87%
--
--
Apr 25, 2025
Geyer (Paul L)
340.35K
0.95%
--
--
Apr 25, 2025
Wilmink (Michael)
224.87K
0.63%
--
--
Apr 25, 2025
RBC Dominion Securities, Inc.
206.63K
0.57%
+59.68K
+40.62%
Mar 31, 2025
RBC Phillips, Hager & North Investment Counsel Inc.
136.20K
0.38%
--
--
Mar 31, 2025
TD Waterhouse Canada, Inc.
104.99K
0.29%
+104.99K
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
